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Abstract. Eleutherine palmifolia (L.) Merr (E. palmifolia) is a typical Central Borneo plant that empirically has many 
benefits in the health sector. E. palmifolia is known to have flavonoids which have anticancer activities. Cancer is the 
leading cause of death throughout the world with the most cancer cases, namely breast and cervical cancer. One of the 
reasons for cancer failure is due to resistance to the use of chemotherapy drugs. One way to overcome to combine 
chemotherapy agents with chemoprevention agents from natural products. This study aims to evaluate the potential 
combination of doxorubicin and extract E. palmifolia on anticancer activity and HeLa cell apoptosis induction. Single 
anticancer activities and combinations were determined by using the MTT method. The effect of the combination on 
apoptosis induction known by the flow cytometry method. The results showed that the anticancer activity of the best 
combination obtained by a combination of 50 ppm doxorubicin and extract E. palmifolia 100 ppm. The apoptosis test 
results showed that the best combination of doxorubicin and extract E. palmifolia could not increase the apoptosis of HeLa 
cervical cancer cells. 
INTRODUCTION 
One of the herbs that are useful as medicine is Eleutherine palmifolia (L.) Merr. (E. palmifolia). E. palmifolia has 
potential as a chemoprevention agent and can be used as an anticancer. It has reported that E. palmifolia ethyl acetate 
extract can inhibit the T47D cell cycle in the G0-G1 phase, extract from ethanolic E. palmifolia can selectively inhibit 
the growth of cervical cancer cells. IC50 (Inhibitory Concentration 50) from E. palmifolia was 40.36 µg / ml with an 
SI value of 4.06 [1]. The presence of flavonoids in these plants is thought to be a class of compounds responsible for 
the apoptotic activity. Flavonoids may inhibit the expression of the enzyme topoisomerase I and II, which play a role 
in screening catalysis and relaxation of DNA. Thus the topoisomerase enzyme inhibitor complex will stabilize and 
cause the topoisomerase enzyme to become stuck. Pinching the topoisomerase enzyme will cause damage and 
continue with the apoptosis process. Regarding the working mechanism, E. palmifolia has the same mechanism of 
action with several cancer drugs, including the doxorubicin [2]. 
Doxorubicin has several working mechanisms, including inhibition of topoisomerase II and DNA intercalation 
resulting in inhibition of DNA and RNA synthesis [3]. Compared to other antibiotics in the anthracycline group, 
doxorubicin is an antibiotic that has the broadest spectrum of clinical activities. However, the side effects of 
doxorubicin are also quite, and the most fatal is cardiomyopathy. Besides, doxorubicin has hepatotoxic side effects 
[4]. The long-term use of doxorubicin can cause resistance due to overexpression of P-glycoprotein (Pgp), which is a 
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 protein that plays a role in removing the drug from the cell, so the cytotoxic potential of doxorubicin in cancer cells 
will decrease [5-7]. Thus giving a dose of doxorubicin is limited to 550 mg/m2 [8]. Doxorubicin is used to treat cancer, 
including cervical cancer.  
EXPERIMENTAL DETAILS 
The material used in this study is E. palmifolia (Eleutherine palmifolia) taken from the city of Batu, East Java. 
Plants determined in the LIPI UPT of the Purwodadi Botanical Gardens Conservation Center with a Certificate of 
Determination number 0064 / IPH.6 / HM / I / 2017. Cancer used in this study is cell line HeLa cervical cancer. The 
cells were obtained from the Cancer Chemoprevention Research Center (CCRC), Faculty of Pharmacy, Gadjah Mada 
University. The materials used for cytotoxic tests are Dimethyl sulfoxide (DMSO), 0.025% trypsin, Phosphate buffer 
saline (PBS), Reagent MTT and Doxorubicin. The material used for apoptosis is BD Pharmingen propidium iodide 
(PI) staining kit, BD Annexin V: FITC Apoptosis Detection and filter.  
This study has been declared ethical approved by the Health Research Ethics Commission of the Faculty of 
Medicine, Brawijaya University, East Java, Indonesia number: 49 / EC / KEPK-S1 / 02/2017. Extraction powder of 
E. palmifolia was carried out using 96% ethanol as a solvent. The solvent volume is 2500 mL. The ratio between 
ingredients and solutions is 1:20. The extraction method used ultrasonic extraction for 20 min [9]. The filtrate was 
evaporated using a rotary evaporator. The concentrated extract dried in the oven. 
Anticancer Combination Test with MTT Method 
 Cells were placed and added 5x105 RPMI media into 96-well plate; six lower right wells emptied for media 
control. The sample solution was made by dissolving DMSO. Each solution made in concentrations of ½ IC50, ¼ IC50, 
3/8 IC50, and 1/8 IC50. IC50 known from extract E. palmifolia is 40.36µg/ml [1], whereas IC50 doxorubicin is 6.33 µg 
/ ml [10]. The cells were taken from the incubator, and the cell media is removed using a 96-well plate reversed above 
the dump and pressed slowly on the tissue. Then the sample solution is inserted into a 96-well plate. Cells incubated 
for 24 hours. Cell media were discarded and washed with PBS. MTT solution added as much as 100 µL to each well. 
Then incubated again for 3-4 hours until formazan formed. After formazan established, the condition of the cells was 
observed in an inverted microscope, and stopper SDS 10% in 0.1 N HCl was added. The plates are wrapped in 
aluminium foil and incubated overnight in a dark place. Then analyzed by ELISA reader. 
Cell Apoptosis Analysis by Flow Cytometry 
The 5x105 cells/wells were planted in a 6-well plate and incubated until normal condition. The cells were treated 
with DMSO solvent (0,25%) and reincubated for 24 hours. At the end of the incubation time, the medium was taken 
and transferred into a tube and centrifuged (371g; 3 min). The supernatant was removed.  The PBS was added to the 
well and PBS was transferred to the microtube, then centrifuged and the supernatant layer was removed. This stage 
was repeated once more and the cells were harvested with trypsin. The cells were transferred into the same microtube 
and then centrifuged (371 g; 3 min). The cells were rinsed with PBS and centrifuged again, and the PBS was discarded 
to get the harvest cells. The sediment was added carefully with PI-Annexin V reagent and immediately homogenized. 
The microtube containing the cell suspension was wrapped in aluminium foil and incubated in a 37 ºC of water bath 
for 5 min. The cell suspension was homogenized again and transferred into a flow cytometer tube using a nylon filter, 
and then ready to be analyzed with a flow cytometer [11]. 
Analysis of MTT Test Result  
The data obtained are in the form of absorbance of each well converted into living cell percent: 
            (%)              =  
(   .             .             )
(   .                .             )
× 100%         (1)                             
Description: Abs: absorbance 
Percentage live cells are calculated to obtain the value of the equation used to calculate the IC50. Combined 
cytotoxicity determined by calculating the interaction index between chemotherapeutic agents with E.  palmifolia, 
using equation 2: 
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     =  ( ) 1 / (  ) 1 + ( ) 2 / (  ) 2            (2) 
Where D1 and D2 are concentrations of samples used in the treatment combination. (Dx) 1 and (Dx) 2 are single 
concentrations that can produce effects as large as those given a combination treatment [12]. The CI or Combination 
Index numbers obtained are interpreted as follows: <0.1 very strong synergistic effect 0.1 - 0.3 strong synergistic 
effect 0.3 - 0.7 synergistic effect 0.7 - 0.9 mild-moderate synergistic effect 0,9 - 1,1 approaching additive effects 1,1 
- 1,45 mild antagonistic effects - moderate 1,45 - 3,3 antagonistic effects> 3,3 strong antagonistic effects - very strong 
Data Analysis of Cell Apoptosis with Flow Cytometry   
Data analysis was performed with cell quest programs to see the percentage of living cells, initial apoptosis, final 
apoptosis, and necrosis. The results of the experiment compared between HeLa cells induced by a combination of E. 
palmifolia and doxorubicin with a single treatment of doxorubicin, a single treatment of E. palmifolia and cell control. 
Per comparison is done by using ANOVA one way followed by test post hoc Tukey's HSD [13]. 
RESULTS 
Anticancer Activity Combination of Doxorubicin and E. palmifolia Extract 
Parameters of anticancer activity in this study seen from cell viability. Cell viability is the number of cells that live 
in each combination. In this research, 16 combination doses were used with treatments below IC50. The smallest cell 
viability is a combination of E. palmifolia with a concentration of 20 ppm and doxorubicin with a concentration of 50 
nM. While the largest is a combination of E. palmifolia with a concentration of 15 ppm and doxorubicin with a 
concentration of 200 nM. The viability of combination cells of doxorubicin and extract is E. palmifolia presented in 
Fig. 1. 
 
 
FIGURE 1. Effect of combination treatment of doxorubicin and E. palmifolia on HeLa cell growth: A) Cell viability due to a 
combination treatment of doxorubicin and E. palmifolia therapy B) Combination Index Treatment of combination doxorubicin 
therapy and E. palmifolia cells as much as 104/wells were planted in the well plate, incubated for 24 h in RPMI media without or 
by treatment with a combination of doxorubicin and E. palmifolia with a predetermined concentration. Cell viability determined 
by the MTT method. The results of this analysis are representations of 2 different experiments with three replications. 
 
After cell viability is known, a combination index is calculated. Combination index is a standard method used to 
evaluate drug combinations [14]. The smaller the value of a combination index, the more synergistic the combination 
will be - the results of the combination index calculation presented in Table 1. 
The results of the combination shown that the synergistic effect obtained in two combinations 1) combination of 
E. palmifolia 10 ppm with 50 nM doxorubicin, and 2) a combination of E. palmifolia 15 ppm with 50 nM doxorubicin. 
The synergistic effect combination was obtained from the combination of E. palmifolia 20 ppm with doxorubicin 50 
nM while the additive combination obtained from a combination of E. palmifolia 5 ppm and doxorubicin 50 nM. Other 
combinations are antagonistic because of the cell resistance to doxorubicin [16]. Other flavonoid compounds which, 
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 when combined with doxorubicin are additive include K4 synthetic flavonoids [17]. Extract E. palmifolia also has an 
antagonistic effect when combined with methotrexate in T47D cells [18]. 
TABLE 1. Results of calculation of combination index 
No 
  
Combination Cell viability 
  
CI 
  
Effect category [15] 
  E. palmifolia Dox 
1 5 50 109.42 ± 6.96 0.92 Additives 
2 5 100 103.89 ± 8.8 1.18 Mild-moderate Antag 
3 5 150 114.86 ± 0.45 2.98 Antagonists 
4 5 200 118.83 ± 4.85 4.79 Strong antagonists 
5 10 50 97.76 ± 13.64 0.67 Synergistic 
6 10 100 110.76 ± 2.37 1.98 Antagonists 
7 10 150 111.21 ± 8, 18 2.75 Antagonists 
8 10 200 124.66 ± 2.37 7.07 Strong antagonists 
9 15 50 94.02 ± 18.7 0.70 Synergistic 
10 15 100 111.21 ± 5.62 2.32 Antagonists 
11 15 150 124.36 ± 2.7 5.99 Antagonists 
12 15 200 125.11 ± 7.65 7.78 Antagonists 
13 20 50 93.12 ± 9.79 0.80 Mild synergistic 
14 20 100 106.73 ± 2, 94 2.09 Antagonists 
15 20 150 112.11 ± 1.55 3.49 Strong antagonists 
16 20 200 110.61 ± 4.26 3.93 Strong antagonists 
The Apoptosis of Combination Treatment of doxorubicin and E. palmifolia Extract on 
HeLa cell 
The appearance of HeLa cells after being treated can be seen in Fig. 1. The HeLa cells are then transferred into the 
cones to tested for apoptosis using a tool of the flow cytometer. The results of the apoptosis study separated from the 
method cell quest. The effects of the separation presented in Fig. 2. 
 
FIGURE 2. The results of the colour separation by the method cell quest on the flow cytometry test results: a) cell control; b) 
after a single doxorubicin induction concentration of 5 nM; c) after inducing E. palmifolia single concentration of 10 ppm; d) 
after being combined with E. palmifolia concentration of 10 ppm and doxorubicin concentration of 5 Nm. 
 
d c 
b a 
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FIGURE 3. Graph of cell distribution results of a flow cytometry test 
 
Data from apoptosis analysis were tested using SPSS 16 for windows. Data were analyzed using ANOVA test one 
way. The results of the significance of the ANOVA test one way are 0.00, which indicates that there are significant 
differences in each sample. The results of the observation showed that the percentage of living cells from combination-
induced cells was higher than the cells that were induced by a single treatment. While the percentage of cells that 
experience apoptosis and necrosis in combination is less than a single treatment, this shows that the combination of 
extract E. palmifolia and doxorubicin cannot increase the apoptosis of HeLa cervical cancer cells. These events are 
expected to occur due to the presence of Fe in cell hemoproteins [19]. Doxorubicin will react with Fe to form 
doxorubicin -Fe complex. The structure of quinones in doxorubicin oxidized to radical semiquinone. Semiquinone 
radicals will react with oxygen to form superoxide and hydrogen peroxide. Superoxide and hydrogen peroxide can 
turn into hydroxyl radicals, which are very reactive with the presence of the doxorubicin -Fe complex [20]. The highly 
reactive hydroxyl radical compounds will bind to flavonoids, which are natural antioxidants [21]. This bond causes 
no mechanism for apoptosis. 
SUMMARY 
The combination of doxorubicin and extract E. palmifolia can provide a synergistic effect in inhibiting Hela cells 
in combination with E. palmifolia 10 ppm: doxorubicin 50 nM and the combination of E. palmifolia 15 ppm: 
doxorubicin 50 nM. The percentage of cells undergoing apoptosis in the combination treatment was 11.42%, whereas 
in a single doxorubicin treatment it was 20.48% and in the therapy E.palmifolia single was 14.66%. This shows that 
the combination of extract E. palmifolia and doxorubicin cannot increase the apoptosis of HeLa cervical cancer cells. 
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